

CITIC Securities (Hong Kong) Limited

**18/F, One Pacific Place
88 Queensway
Hong Kong**

To: The Board of Directors
TYK Medicines, Inc
浙江同源康醫藥股份有限公司
Room 1403-2, Floor 14, Tower A
Changxing World Trade Building
No. 1278 Mingzhu Road
Changxing Economic Development Zone
Huzhou
Zhejiang Province
PRC

Date: August 12, 2024

Dear Sirs,

Proposed global offering and listing of the H shares of TYK Medicines, Inc 浙江同源康醫藥股份有限公司 (the “Company”) on the Main Board of The Stock Exchange of Hong Kong Limited (the “Stock Exchange”) (the “Proposed Listing”)


We refer to the Company’s prospectus dated August 12, 2024 (the “**Prospectus**”) in connection with the Proposed Listing.

We hereby give our consent, and confirm that we have not withdrawn our consent, to the issue of the Prospectus in connection with the Proposed Listing with the inclusion therein of all references to our name, qualifications, statements, confirmations and opinions, in the form and context in which they respectively appear in the Prospectus.

We hereby consent to a copy of this letter being released to the Registrar of Companies in Hong Kong and the Stock Exchange. We also consent to a copy of this letter being made available on display as described in Appendix VIII “Documents Delivered to the Registrar of Companies and Available on Display” to the Prospectus.

For and on behalf of

CITIC Securities (Hong Kong) Limited

A handwritten signature in blue ink, consisting of several loops and a long vertical stroke, positioned above a horizontal line.

Name: Wong Sze Man
Title: Director



Ernst & Young
27/F, One Taikoo Place
979 King's Road
Quarry Ba, Hong Kong

安永會計師事務所
香港鰂魚涌英皇道 979 號
太古坊一座 27 樓

Tel 電話: +852 2846 9888
Fax 傳真: +852 2868 4432
ey.com

Consent letter

August 12, 2024

The Directors

TYK Medicines, Inc

(浙江同源康醫藥股份有限公司)

Room 1403-2, Floor 14, Tower A

Changxing World Trade Building

No. 1278 Mingzhu Road

Changxing Economic Development Zone

Huzhou

Zhejiang Province

PRC

Dear Sirs,

TYK Medicines, Inc (浙江同源康醫藥股份有限公司) (the "Company") and its subsidiaries (the "Group")

Listing on the Main Board of The Stock Exchange of Hong Kong Limited

We refer to the prospectus of the Company dated August 12, 2024 (the "Prospectus") in connection with the proposed initial listing of shares of the Company on the Main Board of The Stock Exchange of Hong Kong Limited, a final proof of which is attached and initialed by us on its front cover for the purpose of identification.

We hereby consent to the inclusion of our accountants' report dated August 12, 2024 on the historical financial information of the Group for the years ended December 31, 2022 and 2023, and three months ended March 31, 2024, and our accountants' report dated August 12, 2024 on the pro forma financial information of the Group for three months ended March 31, 2024 in the Prospectus, and the references to our name in the form and context in which they are included.

This letter is solely being issued in connection with the filing of the Prospectus regarding the listing of the Company's shares on The Stock Exchange of Hong Kong Limited and not for any other purpose.



Yours faithfully,

A handwritten signature in black ink, which appears to be 'Ernst & Young', is written over the printed text.

Certified Public Accountants
Hong Kong

Date: August 12, 2024

The Board of Directors
TYK Medicines, Inc
Room 1403-2, Floor 14, Tower A, Changxing World Trade Building
No. 1278 Mingzhu Road, Changxing Economic Development Zone
Huzhou, Zhejiang Province
PRC

Dear Sirs,

Re: Consent to the issue of the Prospectus of the TYK Medicines, Inc (the "Company")

We refer to the prospectus of the Company dated August 12, 2024 (the "**Prospectus**") in connection with the Global Offering and the proposed listing of the shares of the Company on the Main Board of The Stock Exchange of Hong Kong Limited (the "**Stock Exchange**"). Unless otherwise defined, capitalized terms used herein shall have the same meanings as those defined in the Prospectus.

We hereby give, and confirm that we have not withdrawn our consent to the issue of the Prospectus with the inclusion therein of our name, address, qualifications, opinions, industry report and all references thereto, in the form and context in which they respectively appear in the Prospectus.

We hereby consent to a copy of this letter being released to the Registrar of Companies in Hong Kong and the Stock Exchange. We also consent to a copy of this letter and our industry report referred to above being made available on display as described in Appendix VIII "Documents Delivered to the Registrar of Companies and Available on Display" to the Prospectus.


FROST & SULLIVAN

沙利文

上海市静安区南京西路1717号
会德丰国际广场2504室
2504 Wheelock Square
1717 Nanjing West Road
Shanghai 200040, China
Tel: 86 (21) 5407 5836
Fax: 86 (21) 3209 8500
www.frost.com

Yours faithfully,

For and on behalf of
Frost & Sullivan (Beijing) Inc., Shanghai Branch Co.



Name: Charles Lau
Title: Executive Director



August 12, 2024

The Board of Directors
TYK Medicines, Inc
(浙江同源康醫藥股份有限公司)
Room 1403-2, Floor 14, Tower A
Changxing World Trade Building
No. 1278 Mingzhu Road
Changxing Economic Development Zone
Huzhou
Zhejiang Province
PRC

Dear Sirs,

Re: Consent to the Issue of the Prospectus of TYK Medicines, Inc (浙江同源康醫藥股份有限公司) (the “Company”) in connection with the Global Offering

We, JunHe LLP, refer to the prospectus of the Company dated August 12, 2024 (the “**Prospectus**”) in connection with the proposed global offering and listing of the H shares of the Company on the Main Board of The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”).

We, hereby give, and confirm that we have not withdrawn, our consent (i) to the issue of the Prospectus; and (ii) to the inclusion of all references to our name and our legal opinions in respect of, among other things, the intellectual property interests of the Company and its subsidiaries under the intellectual property laws of the PRC and the United States in the Prospectus (the “**Legal Opinions**”) in the form and context in which they respectively appear.

We also hereby consent (i) to this letter being released to the Registrar of Companies in Hong Kong and the Stock Exchange and referred to in the Prospectus, and (ii) to the copy of this letter and the Legal Opinions dated August 12, 2024 being made available on display as described in Appendix VIII to the Prospectus.



君合律师事务所

Yours faithfully,

For and on behalf of
JunHe LLP

JunHe LLP

August 12, 2024

The Board of Directors
TYK Medicines, Inc
(浙江同源康醫藥股份有限公司)
Room 1403-2, Floor 14, Tower A
Changxing World Trade Building
No. 1278 Mingzhu Road
Changxing Economic Development Zone
Huzhou
Zhejiang Province
PRC

Dear Sirs,

Re: Consent to the Issue of the Prospectus of TYK Medicines, Inc (浙江同源康醫藥股份有限公司) (the “Company”) in connection with the Global Offering

We, JunHe LLP, refer to the prospectus of the Company dated August 12, 2024 (the “**Prospectus**”) in connection with the proposed global offering and listing of the H shares of the Company on the Main Board of The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”).

We, hereby give, and confirm that we have not withdrawn, our consent (i) to the issue of the Prospectus; and (ii) to the inclusion of all references to our name and our legal opinions in respect of, among other things, certain general corporate matters and the property interests of the Company and its subsidiaries under PRC law in the Prospectus (the “**Legal Opinions**”) in the form and context in which they respectively appear.

We also hereby consent (i) to this letter being released to the Registrar of Companies in Hong Kong and the Stock Exchange for the purpose of the registration of the Prospectus and referred to in the Prospectus, and (ii) to the copy of this letter and the Legal Opinions dated August 12, 2024 being made available on display as described in Appendix VIII to the Prospectus.



君合律师事务所

Yours faithfully,

For and on behalf of
JunHe LLP

JunHe LLP

To: **TYK Medicines, Inc**
浙江同源康醫藥股份有限公司
Room 1403-2, Floor 14, Tower A, Changxing World Trade Building
No. 1278 Mingzhu Road, Changxing Economic Development Zone
Huzhou, Zhejiang Province
PRC

August 12, 2024

Dear Sirs,

TYK Medicines, Inc 浙江同源康醫藥股份有限公司 (the "Company") – Consent Letter

We refer to the prospectus of the Company dated August 12, 2024 (the "**Prospectus**") in connection with the Global Offering and the proposed listing of the H shares of the Company on the Main Board of The Stock Exchange of Hong Kong Limited (the "**Stock Exchange**"). Unless otherwise defined, capitalized terms used herein shall have the same meanings as those defined in the Prospectus.

We hereby give, and confirm that we have not withdrawn our consent to the issue of the Prospectus with the inclusion therein of our name, address, qualifications, opinions, property valuation report and all references thereto, in the form and context in which they respectively appear in the Prospectus.

We hereby consent to you releasing this letter to the Registrar of Companies in Hong Kong and the Stoke Exchange for the purpose of the registration of the Prospectus and referring to it in the Prospectus. We also hereby consent to a copy of this letter and our property valuation report being made available on display as described in Appendix VIII "Documents Delivered to the Registrar of Companies and Available on Display" to the Prospectus.



Yours faithfully,

For and on behalf of
AVISTA Valuation Advisory Limited

A handwritten signature in black ink, appearing to read 'Vincent Pang', written over a horizontal line.

Name: Vincent Pang

Title: Managing Partner